These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 25666998)

  • 41. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?
    Stancu S; Bârsan L; Stanciu A; Mircescu G
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):409-16. PubMed ID: 20019121
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
    Bailie GR
    Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Iron Treatment Strategies in Nondialysis CKD.
    Macdougall IC
    Semin Nephrol; 2016 Mar; 36(2):99-104. PubMed ID: 27236130
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of hepatic and cardiac iron deposition during standard treatment of anaemia in haemodialysis.
    Holman R; Olynyk JK; Kulkarni H; Ferrari P
    Nephrology (Carlton); 2017 Feb; 22(2):114-117. PubMed ID: 26824431
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Iron therapy in patients with heart failure. A straight shot.
    Beck-da-Silva L; Rohde LE; Clausell N
    Int J Cardiol; 2013 Oct; 168(5):5071-2. PubMed ID: 23931974
    [No Abstract]   [Full Text] [Related]  

  • 46. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management.
    Cappellini MD; Comin-Colet J; de Francisco A; Dignass A; Doehner W; Lam CS; Macdougall IC; Rogler G; Camaschella C; Kadir R; Kassebaum NJ; Spahn DR; Taher AT; Musallam KM;
    Am J Hematol; 2017 Oct; 92(10):1068-1078. PubMed ID: 28612425
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial-IRON Trial.
    Núñez J; Miñana G; Cardells I; Palau P; Llàcer P; Fácila L; Almenar L; López-Lereu MP; Monmeneu JV; Amiguet M; González J; Serrano A; Montagud V; López-Vilella R; Valero E; García-Blas S; Bodí V; de la Espriella-Juan R; Lupón J; Navarro J; Górriz JL; Sanchis J; Chorro FJ; Comín-Colet J; Bayés-Genís A;
    J Am Heart Assoc; 2020 Feb; 9(4):e014254. PubMed ID: 32067585
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients.
    Deira J; González-Sanchidrián S; Polanco S; Cebrián C; Jiménez M; Marín J; Gómez-Martino JR; Fernández-Pereira L; Tabernero J
    Ren Fail; 2016 Aug; 38(7):1076-81. PubMed ID: 27197731
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Functional iron deficiency and diastolic function in heart failure with preserved ejection fraction.
    Kasner M; Aleksandrov AS; Westermann D; Lassner D; Gross M; von Haehling S; Anker SD; Schultheiss HP; Tschöpe C
    Int J Cardiol; 2013 Oct; 168(5):4652-7. PubMed ID: 23968714
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia.
    Beck-da-Silva L; Rohde LE; Pereira-Barretto AC; de Albuquerque D; Bocchi E; Vilas-Boas F; Moura LZ; Montera MW; Rassi S; Clausell N
    J Card Fail; 2007 Feb; 13(1):14-7. PubMed ID: 17338998
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial.
    Singh H; Reed J; Noble S; Cangiano JL; Van Wyck DB;
    Clin J Am Soc Nephrol; 2006 May; 1(3):475-82. PubMed ID: 17699248
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Heart failure in patients with kidney disease and iron deficiency; the role of iron therapy.
    Cases Amenós A; Ojeda López R; Portolés Pérez JM;
    Nefrologia; 2017; 37(6):587-591. PubMed ID: 28610806
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intravenous iron sucrose versus oral iron ferrous sulfate for antenatal and postpartum iron deficiency anemia: a randomized trial.
    Froessler B; Cocchiaro C; Saadat-Gilani K; Hodyl N; Dekker G
    J Matern Fetal Neonatal Med; 2013 May; 26(7):654-9. PubMed ID: 23130909
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia.
    Anker SD; Colet JC; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Mori C; von Eisenhart Rothe B; Pocock S; Poole-Wilson PA; Ponikowski P;
    Eur J Heart Fail; 2009 Nov; 11(11):1084-91. PubMed ID: 19875408
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
    Leszek P; Kruszewski M
    Eur Heart J; 2008 Feb; 29(4):565-6; author reply 566-7. PubMed ID: 18192702
    [No Abstract]   [Full Text] [Related]  

  • 56. Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis.
    Gutzwiller FS; Pfeil AM; Comin-Colet J; Ponikowski P; Filippatos G; Mori C; Braunhofer PG; Szucs TD; Schwenkglenks M; Anker SD
    Int J Cardiol; 2013 Oct; 168(4):3878-83. PubMed ID: 23870642
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of Total Dose Infusion of Iron Intravenously in Patients With Acute Heart Failure and Anemia (Hemoglobin < 13 g/dl).
    Kaminsky BM; Pogue KT; Hanigan S; Koelling TM; Dorsch MP
    Am J Cardiol; 2016 Jun; 117(12):1942-6. PubMed ID: 27161817
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improvement of anemia with erythropoietin and intravenous iron reduces sleep-related breathing disorders and improves daytime sleepiness in anemic patients with congestive heart failure.
    Zilberman M; Silverberg DS; Bits I; Steinbruch S; Wexler D; Sheps D; Schwartz D; Oksenberg A
    Am Heart J; 2007 Nov; 154(5):870-6. PubMed ID: 17967592
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy, safety and prognostic benefit of intravenous iron therapy with ferric carboxymaltose in patients with heart failure and left ventricular dysfunction.
    Robles-Mezcua A; González-Cruces N; Ruiz-Salas A; Morcillo-Hidalgo L; Robledo-Carmona J; Gómez-Doblas JJ; de Teresa E; García-Pinilla JM
    Int J Cardiol; 2016 Jan; 202():118-20. PubMed ID: 26397399
    [No Abstract]   [Full Text] [Related]  

  • 60. Intravenous iron sucrose versus oral iron in treatment of iron deficiency anemia in pregnancy: a randomized clinical trial.
    Kochhar PK; Kaundal A; Ghosh P
    J Obstet Gynaecol Res; 2013 Feb; 39(2):504-10. PubMed ID: 22925176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.